Corcept Therapeutics | CORT - Assets


Corcept Therapeutics reported $814.88M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Aurora Cannabis CAD 775.29M 18.43M Dec/2025
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Canopy Growth CAD 1.11B 36.35M Dec/2025
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.21B 56.38M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026